Although anaphylaxis during anaesthesia is a rare condition, its diagnosis has important implications, particularly in providing safe future anaesthesia. To do this requires the determination of both the nature of the reaction and the drug or other agents responsible for the reaction. Elevated levels of mast cell tryptase (MCT) approximately one to four hours after a reaction occurs is the single most useful test to confirm an anaphylactic event [1] [2] [3] [4] [5] [6] but this test does not identify the causative agent. The most valuable test to identify the drug responsible is skin testing, which is usually carried out four to six weeks after the reaction 7, 8 . The radioimmunoassays (RIAs) for the detection of drug-reactive IgE antibodies [9] [10] [11] [12] [13] [14] provide important supplementary tests. The RIAs can also sometimes confirm the diagnosis by identifying the drug responsible in patients whose skin tests are negative and the in vitro tests offer the advantage that they can be carried out with blood taken at the time of the reaction. This increases the tests' value in patients following cancellation of surgery due to known or suspected sensitivity and when surgery must be performed before skin testing can be reliably undertaken. The major limitations to the use of the RIAs for neuromuscular blocking drugs (NMBDs) are that the preparation of the materials used in the tests is usually only possible in dedicated laboratories and, with the exception of the assay to detect IgE antibodies to succinylcholine 10 , the correlation of results obtained with other RIAs for NMBDs with skin test results is not always good 4, 15 . In 1983 we showed that morphine was a potent inhibitor of the binding in vitro of IgE antibodies to NMBDs in sera from some subjects who had experienced an anaphylactic reaction following exposure to these drugs during anaesthesia 9 . The mechanism of this inhibition was shown to be cross-reactive recognition of substituted ammonium groups which are shared by the NMBDs, morphine and a number of other drugs and chemicals 9, 16 . Since that time, a range of available NMBDs and morphine have been used in routine RIA screening of sera from subjects with suspected anaphylaxis to a NMBD following drug administration during anaesthesia. In an attempt to determine the value of morphine in solid-phase form as a potential diagnostic aid in suspected cases of NMBD-induced anaphylaxis, results of RIAs for the detection of drug-reactive IgE antibodies were compared with the clinical picture and skin test findings in a large group of patients defined as experiencing anaphylaxis on the basis of a positive serum MCT result and a positive skin test to one or more NMBDs.
METHODS AND PATIENTS
Intradermal testing was carried out four to six weeks after the reaction with drugs diluted to concentrations determined as unlikely to produce reactions as a result of direct histamine release 7, 8 . RIAs for drugs [9] [10] [11] [12] [13] [14] and the immunoassay for tryptase determination have been described 2, 5 . All serum samples for MCT determination were taken 30 minutes to four hours after the adverse reaction 17 . Six patients who died but survived for four hours after the reaction and had a positive serum tryptase level in the post mortem blood were included in the study.
Results of the immunoassays were considered in the following groups: Group 1. Patients who had an elevated serum MCT level and showed a positive skin test to at least one NMBD. Group 2. Patients who had an elevated serum MCT level and showed a positive skin test to a drug other than a NMBD. Group 3. Patients who had suspected anaphylaxis but a serum MCT level that was not elevated and skin tests to NMBDs were negative. Group 4. Patients who had suspected anaphylaxis, serum MCT levels were not elevated and no skin-testing was performed. Control sera were obtained from normal, healthy laboratory workers and cord sera, used as an "IgE free" control, from the Department of Obstetrics, Royal North Shore Hospital.
Specificity, sensitivity, efficacy and positive predictive values for the morphine and NMBD RIAs were calculated using the methods of Galen and Gambino 18 .
RESULTS
With the aim of subdividing the 347 subjects suspected of experiencing an anaphylactic reaction following anaesthesia into homogeneous groups for meaningful comparison, MCT levels were determined in the serum of each subject. Subjects with elevated MCT levels were then further divided into those who were skin test positive to a NMBD given at the time of the reaction (group 1, 118 subjects) and those who were skin-test-negative to these drugs but positive to a different drug given at the time of the reaction (group 2, 45 subjects). Of the 184 subjects whose serum MCT levels were not elevated, 56 were skin-test-negative to the drugs administered (group 3) while in 128 cases, skin-tests were not performed (group 4).
Results of the RIAs for the NMBDs and morphine carried out on the sera from each of the four different groups are shown in Table 1 . Whereas in group 1, IgE antibodies to the NMBD given at the time of the reaction were detected in only 56 of 108 subjects, 100 of 118, or 85% of subjects had IgE antibodies that reacted with morphine. Breaking down these numbers into the subgroups formed from the eight different NMBDs showed that the RIA to detect suxamethonium sensitivity was the drug test that correlated best with skin-test findings (~70%). IgE was detected in only two of six and two of eight subjects who reacted following administration of atracurium and alcuronium respectively, while the frequencies of antibodies detected to the steroid-like NMBDs vecuronium, pancuronium and rocuronium were also low. By contrast, the morphine RIA picked up 67 of 69 (~97%), nine of 10 and 15 of 15 reactors to suxamethonium, vecuronium and rocuronium respectively. Only four of eight and, interestingly, only three of 12 reactors to alcuronium and atracurium respectively reacted positively to the morphine solid phase (Table 1) . In groups 2, 3 and 4, IgE antibodies to NMBDs were not detected in any of the sera but antibodies to morphine were detected in two, one and two subjects respectively. Two patients had elevated MCT levels, positive skin-tests to a drug (not a NMBD) given prior to the reaction, and morphine antibodies. One reacted to flucloxacillin and one to morphine. The one patient with a positive morphine RIA, negative skin-tests and a normal MCT level had a convincing clinical reaction and may be allergic to alcuronium. Two patients in whom MCT was not elevated and no skin-testing was performed had low levels of IgE antibodies reactive with morphine (uptakes of 3.1% and 3.4%; upper limit of uptake with normal sera, 3%).
DISCUSSION
One of the major uncertainties in evaluating diagnostic test results in suspected cases of anaphylaxis to anaesthetic drugs is the possibility that a negative result to the suspected drug(s) may occur in a subject who experienced some or all of the signs associated with an anaphylactic or anaphylactoid reaction due to another, non-allergic, mechanism. In such cases it is difficult to determine whether the result is due to a weakness inherent in the test, such as lack of sensitivity, or whether the negative finding truly reflects the real situation 8 . Use of the MCT assay enables the investigator to determine whether or not a suspected reaction was truly anaphylactic; that is, it identifies an homogeneous study group since, when serum tryptase is elevated, an anaphylactic (or less commonly an anaphylactoid) reaction is the most likely mechanism 19 . When this information is used with results of skin-test responses to drugs, homogeneous groups of anaphylactic and non-anaphylactic reactors can be further studied in vitro for the presence or absence of drug-reactive serum IgE antibodies. Results presented here demonstrate how closely the drug RIAs for IgE antibodies correlate with the group (group 1) defined by elevated MCT levels and positive skin test responses to NMBDs compared to the other three groups. Further, the absence or low frequency of positive reactions in groups 2, 3 and 4 (Table 1) suggests that positive results to both the morphine and NMBD RIAs are clinically significant; that is, likely to be associated with reactions (Table 2) .
Our early studies showed that IgE antibodies in the sera of subjects who had anaphylaxis to a NMBD were complementary to substituted ammonium groups on the NMBDs and other drugs and chemicals including morphine 16 . This led to the hypothesis that cross-linking of mast-cell-bound IgE antibodies, the prelude to allergic mediator release, may occur via the ammonium ion antigenic determinants on protein-bound or even free NMBDs, since all NMBDs are at least divalent with respect to substituted ammonium groups 9 . Experimental verification of release of mediators from human leucocytes by free NMBDs appears to have been provided 20, 21 . Compounds such as morphine that cross-react with NMBD-reactive antibodies via a single substituted ammonium group would not, in the free state, be expected to mediate allergic release by cross-linking IgE bound to mast cells and basophils. Although anaphylaxis to morphine has been reported together with morphine-reactive IgE antibodies 12 , allergic reactions to the opiate are rare.
What is apparent from the results reported here is that the morphine RIA proved to be the best single in vitro test for the detection of IgE antibodies that react with substituted ammonium ions and hence for the in vitro diagnosis of NMBD-induced anaphylaxis. Detection of IgE antibodies in the morphine RIA showed an 86% correlation with the 118 subjects with an elevated MCT level and identified as skin-testpositive to an NMBD given immediately prior to the reaction. This compares very favourably with the NMBD RIAs where results with the compounds with steroid-like structures (vecuronium, pancuronium, rocuronium) are poor, chiefly because of technical difficulties arising from the chemical structures of these drugs 14 . For the morphine assay, correlations between the detection of IgE antibodies on the one hand and the subjects with MCT elevation and a positive skin-test (group 1, Table 1 ) on the other, were excellent (90-97%) for suxamethonium, vecuronium and rocuronium. Interestingly, only three of 12 patients who reacted to atracurium were picked up as positive in the morphine RIA. A possible explanation for this is that the reactions were not true IgEmediated anaphylactic reactions. Lorenz's group has identified a group of patients who have extreme reactions to the direct histamine-releasing effects of atracurium 22 and, in a situation similar to that described with Haemaccel R, such reactions could be associated with positive skin-tests and elevated MCT levels 19 . The relevance of these findings is that the morphine RIA offers an improvement over the battery of RIAs for individual NMBDs (Table 2 ) and provides a valuable adjunct to skin-test and tryptase determination in the diagnosis of allergic reactions to NMBDs. Its usefulness is particularly apparent when a diagnosis is needed in skin-test-negative patients or prior to skin-tests which, optimally, are usually carried out about one month after a reaction 7, 8 . In addition to its superior performance, the use of the morphine RIA instead of the battery of tests for individual NMBDs greatly reduces the time, labour and cost of in vitro testing in cases of suspected anaphylaxis to NMBDs and we have altered our laboratory practice to perform only the morphine RIA.
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